中华生物医学工程杂志
中華生物醫學工程雜誌
중화생물의학공정잡지
CHINESE JOURNAL OF BIOMEDICAL ENGINEERING
2010年
1期
66-69
,共4页
陆骊工%黄国敏%胡宝山%李勇%邵培坚
陸驪工%黃國敏%鬍寶山%李勇%邵培堅
륙려공%황국민%호보산%리용%소배견
肿瘤转移%椎体成形术%骨代用品%缓释氟尿嘧啶%生存质量
腫瘤轉移%椎體成形術%骨代用品%緩釋氟尿嘧啶%生存質量
종류전이%추체성형술%골대용품%완석불뇨밀정%생존질량
Neoplasm metastasis%Vertebroplasty%Bone substitutes%Sustained - release fluorouracil%Life quality
目的 评估经皮椎体成形术(PVP)联合缓释氟尿嘧啶治疗椎体转移瘤的疗效及安全性.方法 入选椎体转移瘤患者共72例.其中PVP+缓释氟尿嘧啶组37例,单纯PVP 35例,通过临床症状、生存分析及影像学评估疗效及安全性.结果 PVP+缓释氟尿嘧啶组椎体肿瘤局部控制率67.6%(25,37),疼痛缓解率达89.2%(33,37);单纯PVP组椎体肿瘤局部控制率42.9%(15,35),疼痛缓解率85.7%(30/35),两组间局部肿瘤控制率差异有统计学意义(P=0.035).两组病例的生活质量、疼痛缓解及生存期差异无统计学意义(P值分别为0.124、0.462和0.498).结论 经皮椎体成形术联合缓释氟尿嘧啶治疗椎体转移瘤是安全、有效的新方法.可明显缓解晚期恶性肿瘤椎体转移带来的剧烈疼痛,改善患者生存质量,并对椎体转移病灶具有一定控制作用.
目的 評估經皮椎體成形術(PVP)聯閤緩釋氟尿嘧啶治療椎體轉移瘤的療效及安全性.方法 入選椎體轉移瘤患者共72例.其中PVP+緩釋氟尿嘧啶組37例,單純PVP 35例,通過臨床癥狀、生存分析及影像學評估療效及安全性.結果 PVP+緩釋氟尿嘧啶組椎體腫瘤跼部控製率67.6%(25,37),疼痛緩解率達89.2%(33,37);單純PVP組椎體腫瘤跼部控製率42.9%(15,35),疼痛緩解率85.7%(30/35),兩組間跼部腫瘤控製率差異有統計學意義(P=0.035).兩組病例的生活質量、疼痛緩解及生存期差異無統計學意義(P值分彆為0.124、0.462和0.498).結論 經皮椎體成形術聯閤緩釋氟尿嘧啶治療椎體轉移瘤是安全、有效的新方法.可明顯緩解晚期噁性腫瘤椎體轉移帶來的劇烈疼痛,改善患者生存質量,併對椎體轉移病竈具有一定控製作用.
목적 평고경피추체성형술(PVP)연합완석불뇨밀정치료추체전이류적료효급안전성.방법 입선추체전이류환자공72례.기중PVP+완석불뇨밀정조37례,단순PVP 35례,통과림상증상、생존분석급영상학평고료효급안전성.결과 PVP+완석불뇨밀정조추체종류국부공제솔67.6%(25,37),동통완해솔체89.2%(33,37);단순PVP조추체종류국부공제솔42.9%(15,35),동통완해솔85.7%(30/35),량조간국부종류공제솔차이유통계학의의(P=0.035).량조병례적생활질량、동통완해급생존기차이무통계학의의(P치분별위0.124、0.462화0.498).결론 경피추체성형술연합완석불뇨밀정치료추체전이류시안전、유효적신방법.가명현완해만기악성종류추체전이대래적극렬동통,개선환자생존질량,병대추체전이병조구유일정공제작용.
Objective To evaluate the efficacy and safety of percutaneous vertebroplasty (PVP) combined with sustained-release fluorouracil for the treatment of vertebral metastasis tumor. Methods A total of 72 cases with vertebral metastasis tumor were enrolled in the study. Thirty-seven cases underwent percutaneous vertebroplasty combined with sustained -release fluorouracil, 35 underwent percutaneous vertebroplasty alone. Efficacy and safety were evaluated through clinical symptoms, survival analysis and radiology. Results Local tumor control and pain relief were achieved in 67.6% (25/37) and 89.2% (33/37) of the patients treated by percutaneous vertebroplasty combined with sustained-release fluorouracil combined, in 42.9% (15/35) and 85.7% (30/35) of those treated with percutaneous vertebroplasty alone. Significant difference was found between two groups for the local tumor control rate (P=0.035), but not for the quality of life, pain relief and survival (P=0.124, 0.462, 0.498, respectively). Conclusions The new treatment using percutaneous vertebroplasty combined with sustained-release fluorouracil for vertebral metastases is safe and effective, which substantially relieves the severe pain in patient with advanced vertebral invasion, and also improves the quality of life and oncological control.